Publication: Efecto del compuesto correlacionado de hexosa activo (AHCC) en patologías inflamatorias intestinales: triquinosis y enfermedad inflamatoria intestinal (EII)
Loading...
Official URL
Full text at PDC
Publication Date
2021-09-08
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
El AHCC es un producto natural descubierto en 1986 y patentado por la empresa japonesa Amino up, que se obtiene a partir de la fermentación del micelio del hongo L. edodes. Está descrito como un nutracéutico o un inmunomodulador por su capacidad para modular la respuesta inmune ante retos de distinta etiología (Corradetti et al., 2019). Actualmente, se emplea como tratamiento concomitante en pacientes oncológicos, ya que disminuye los efectos generalizados de la quimioterapia (D'Orta A, 2018; Ritz, 2008; B. Sun et al., 2009; S. Wang et al., 2009). En el presente trabajo, se quisieron probar los efectos del AHCC en un órgano donde la regulación del sistema inmune es fundamental: el intestino. Para ello, se recurrió a varios modelos: el modelo murino de triquinosis y a modelos de enfermedad inflamatoria intestinal (EII), tanto aguda como crónica (Brennan & Garrett, 2016; Gearry, 2016)...
AHCC is a natural product discovered in 1986 and patented by the Japanese company Amino up, which is obtained from the fermentation of the mycelium of the L. edodes fungus. It is described as a nutraceutical or an immunomodulator due to its ability to modulate the immune response to challenges of different etiology (1). Currently, it is used as concomitant treatment in cancer patients, since it reduces the generalized effects of chemotherapy (2-5).In the present work, we wanted to test the effects of AHCC in an organ where the regulation of the immune system is fundamental: the intestine. To do this, several models were used: the murine model of trichinosis and models of inflammatory bowel disease (IBD), both acute and chronic (6, 7)...
AHCC is a natural product discovered in 1986 and patented by the Japanese company Amino up, which is obtained from the fermentation of the mycelium of the L. edodes fungus. It is described as a nutraceutical or an immunomodulator due to its ability to modulate the immune response to challenges of different etiology (1). Currently, it is used as concomitant treatment in cancer patients, since it reduces the generalized effects of chemotherapy (2-5).In the present work, we wanted to test the effects of AHCC in an organ where the regulation of the immune system is fundamental: the intestine. To do this, several models were used: the murine model of trichinosis and models of inflammatory bowel disease (IBD), both acute and chronic (6, 7)...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 04-06-2021